Evaluation of thrombotic children with malignancy.

Area of Science:

• Pediatric Hematology
• Oncology
• Thrombosis Research

Background:

• Malignancy is a significant risk factor for thrombosis in children.
• Understanding inherited and acquired prothrombotic factors is crucial for managing pediatric thrombosis.
• Previous studies highlight the association between cancer and blood clots in young patients.

Purpose of the Study:

• To evaluate inherited and acquired prothrombotic risk factors in children with malignancy and thrombosis.
• To emphasize the importance of inherited prothrombotic risk factors in this population.
• To identify specific genetic mutations and clinical factors contributing to thrombosis.

Main Methods:

• Retrospective analysis of 37 children with thrombosis and malignancy.
• Evaluation of thrombosis timing, central venous line (CVL) use, L-asparaginase, and infections.
• Analysis of genetic mutations (Factor V G1691A, Prothrombin G20210A), protein deficiencies (C, S, antithrombin III), Factor VIII, lipoprotein(a), and antiphospholipid antibodies.

Main Results:

• Malignancy was present in 9.5% of children with thrombosis (37 out of 387).
• 54% of patients had one or two additional prothrombotic risk factors beyond CVL and L-asparaginase.
• Identified mutations included Factor V G1691A (8 patients), Prothrombin G20210A (1 patient), and elevated Factor VIII/lipoprotein(a) (2 and 4 patients, respectively).

Conclusions:

• Malignancy is a key risk factor for childhood thrombosis.
• The risk of thrombosis is amplified by the presence of additional prothrombotic factors.
• Screening high-risk pediatric cancer patients for prothrombotic factors is recommended for prevention.